Test Price
2,800 AED✅ Home Collection Available
DECR1 Gene Analysis (2,4-Dienoyl-CoA Reductase 1) Genetic Test in UAE – 2800 AED
Executive Summary & Core Metrics
Executive Summary
The DECR1 Gene Analysis utilises targeted next-generation sequencing (NGS) to detect pathogenic variants in the 2,4-dienoyl-CoA reductase 1 gene, achieving 99.9% diagnostic sensitivity for mitochondrial fatty acid oxidation disorders. This ISO 9001:2015 certified assay supports early risk stratification for unexplained hypoglycaemia, cardiomyopathy, and recurrent metabolic crises. The service includes temperature-controlled home phlebotomy, post-test telephonic guidance by a DHA-licensed medical geneticist, and direct insurance billing verification via WhatsApp.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified NGS processing with ≥100x coverage depth.
- Premium Logistics: VIP mobile phlebotomy & temperature-controlled cold-chain home collection (daily 8 AM – 11 PM).
- Clinical Guidance: Post-test telephonic consultation with a DHA-licensed consultant medical geneticist for result interpretation.
- Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731 – we coordinate directly with your provider.
Test Overview & Methodology
The DECR1 genetic test sequences the entire coding region of the 2,4-dienoyl-CoA reductase 1 gene using targeted amplicon capture NGS. This approach identifies pathogenic single-nucleotide variants and small indels linked to inherited fatty acid oxidation disorders, enabling precise metabolic risk assessment for patients presenting with unexplained hypoglycaemia, skeletal myopathy, or dilated cardiomyopathy. Results are reported as pathogenic variant detected, variant of uncertain significance, or no clinically relevant variant, accompanied by a comprehensive interpretive clinical report.
| Feature | Our Test: DECR1 Targeted NGS | Closest Alternative: Whole Exome Sequencing (WES) |
|---|---|---|
| Precision | >99.9% sensitivity for all known DECR1 variants; high coverage depth (≥100x) | Broad genomic analysis; often lower depth at DECR1 locus, potential for missed variants |
| Methodology | Next Generation Sequencing (NGS) with targeted amplicon capture | Whole Exome Sequencing via hybrid capture |
| Speed & Cost | 3–4 Weeks | 2800 AED | 6–8 Weeks | 6000–8000 AED |
Physician Insight & Safety Protocols
Insight from Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“Genetic testing for DECR1 provides definitive diagnostic clarity when integrated with a full metabolic profile and detailed family pedigree. A negative result does not exclude all inborn errors of metabolism, and every finding must be interpreted in the context of the patient’s complete clinical picture. Pre-test genetic counselling is mandatory to ensure informed consent and to discuss implications for at-risk relatives.”
Advisory: Medication Continuity
Important: Do not discontinue any prescribed medication or supplement without explicit consultation with your treating physician. Genetic results may inform future treatment adjustments but should never replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: This test is not intended for prenatal diagnosis without prior confirmation via amniocentesis or chorionic villus sampling. Chain-of-custody documentation is mandatory if results are to be used for legal proceedings.
- Emergency Red Flags – Seek Immediate Care: Sudden onset lethargy, intractable vomiting, severe hypoglycaemia (blood glucose < 50 mg/dL), unexplained seizures, or altered consciousness. These may indicate an acute metabolic crisis requiring urgent medical intervention.
Patient FAQ & Clinical Guidance
1. What is the DECR1 gene test and who should consider it?
A: The DECR1 gene test is a targeted NGS analysis that identifies pathogenic variants in the 2,4-dienoyl-CoA reductase 1 gene. It is recommended for individuals with unexplained hypoglycaemia, muscle weakness, cardiomyopathy, or a family history of fatty acid oxidation disorders.
2. How is the sample collected and what results can I expect?
A: A peripheral whole blood sample is collected via venipuncture at your home through our VIP mobile phlebotomy service (available 8 AM – 11 PM). Results are delivered in 3–4 weeks as a clinical report indicating “pathogenic variant detected,” “variant of uncertain significance,” or “no clinically relevant variant,” with full interpretive guidance.
3. Is genetic counselling required before testing?
A: Yes, a pre-test genetic counselling session with our consultant medical geneticist is mandatory. This session reviews your family history, constructs a detailed pedigree, and discusses the potential implications of results for you and your at-risk relatives, ensuring fully informed consent.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
This laboratory operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted during transmission and storage, with access restricted to authorised clinical personnel. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Name: DNA Labs UAE | DHA Facility License: 1143 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139)
Medical Reviewer: Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403. All clinical content is evidence-based and reviewed annually in accordance with UAE genetic testing guidelines.
Clinical & Logistical Metadata
| Test Name | DECR1 Gene Analysis (2,4-Dienoyl-CoA Reductase 1) – Targeted NGS |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available Daily 8 AM – 11 PM) |
| Methodology Used | Next Generation Sequencing (NGS) – Targeted Amplicon Capture, ≥100x coverage |
| ICD-10-CM Code | E71.318, Z15.89, E88.89 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians